文献速递炎症性肠病

采用药物耐受性检测法检测抗英夫利西单抗抗体的临床意义:TAXIT试验的事后分析

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
PubMed 文献 · Gut · 2017-04-27

该研究对TAXIT随机对照试验中76例筛查时英夫利西单抗谷浓度<3 µg/mL的患者进行事后分析,用药物耐受性检测法复测221份血清样本的抗药抗体。药物耐受性检测法使免疫原性检出率从21%升至63%,低浓度抗药抗体在剂量强化后过半消失且临床无关,高浓度抗药抗体持续存在并需更高累积剂量和费用。

要点

  • 药物耐受性检测法使筛查时抗药抗体检出率从21%升至63%。
  • 剂量优化后检出率从0%升至51%,试验结束时从3%升至42%。
  • 高浓度抗药抗体组需更高累积剂量和费用,作者认为可考虑主动换药。

核心结论

  • 剂量强化后,药物敏感检测法无法检出的低浓度抗药抗体在超过一半患者中随时间消失且临床无关。
  • 高浓度抗药抗体通常也能被药物敏感检测法检出,随时间持续存在并需要更高的累积剂量和药物费用。
  • 作者认为在高浓度抗药抗体组中,主动换药可能更具成本效益。

研究设计与样本

  • TAXIT随机对照试验的事后分析,纳入76例筛查时英夫利西单抗谷浓度<3 µg/mL的患者,复测221份血清样本。
  • 患者在随机化前接受剂量递增以使谷浓度达到3 µg/mL至7 µg/mL,按筛查时抗药抗体浓度分为四分位组(Q1-Q4)。

主要发现

  • 药物耐受性检测法使免疫原性检出率从21%(药物敏感检测法)升至63%(筛查时),从0%升至51%(优化后),从3%升至42%(试验结束时)。
  • ADA Q4组达到目标谷浓度所需累积英夫利西单抗剂量为2390(880-2998)mg,药物费用为€10 712(4120-13 596)。
  • ADA阴性患者药物费用为€2060(1648-3296),ADA Q1/Q2组分别为€2060(1648-4120)和€2060(1751-3296),p<0.001。
  • ADA Q4组中除一例患者外,其余患者用药物敏感检测法也均为抗药抗体阳性。

临床怎么用

  • 作者认为,对于高浓度抗药抗体且药物敏感检测法也阳性的患者,主动换药可能更具成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical relevance of antidrug antibodies (ADAs) measured using a drug-tolerant assay in a post hoc analysis of the Trough Concentration (TC) Adapted Infliximab Treatment (TAXIT) randomised controlled trial. DESIGN: ADA in serum samples (n=221) of 76 patients enrolled in TAXIT, who presented with an infliximab TC <3 µg/mL at screening, were reanalysed after optimisation and at the end of the study using a drug-tolerant ADA assay. Patients underwent dose escalation to achieve therapeutic TCs between 3 µg/mL and 7 µg/mL prior to randomisation. Patients were grouped into quartiles (Q1-4) according to ADA concentration at screening. RESULTS: Using a drug-tolerant assay, the immunogenicity detection rate increased from 21% (drug-sensitive assay) to 63% at screening, from 0% to 51% after optimisation and from 3% to 42% at the end of TAXIT. Patients in ADA Q4 required a higher cumulative infliximab dose (2390 (880-2998) mg) to achieve target TCs, resulting in a higher drug cost (€10 712 (4120-13 596)) compared with ADA-negative patients (€2060 (1648-3296)) and patients in ADA Q1/Q2 (€2060 (1648-4120)/€2060 (1751-3296), p<0.001). However, all but one patient belonging to ADA Q4 were also ADA-positive using a drug-sensitive assay. CONCLUSIONS: Upon dose intensification, low concentration ADAs, not detectable using a drug-sensitive assay, disappear in more than half of the patients over time and are clinically non-relevant. In contrast, high concentration ADAs which are typically also detected in a drug-sensitive assay, persist over time and necessitate a higher cumulative dose and drug cost. In the latter group, proactive drug switching may be more cost-efficient. CLINICAL TRIALS REGISTER: 2011-002061-38; Post-results.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Van Stappen T, Vande Casteele N, Van Assche G, et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2017. PMID: 28450388. doi:10.1136/gutjnl-2016-313071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。